N/A
Completed N=330
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
Source: ClinicalTrials.gov NCT00794365 ↗Enrolled (actual)
330
Serious AEs
0.0%
Results posted
Dec 2010
Primary outcomePrimary: Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 4 — 58.79 percentage of participants
Summary
The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks among Filipino smokers.
The secondary objective is to further evaluate the effectiveness of Varenicline (Champix™) as an aid in smoking cessation based on the 7-day point prevalence of smoking cessation
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 4 |
58.79 | — |
| PRIMARY Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 8 |
61.52 | — |
| PRIMARY Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 12 |
57.58 | — |
Eligibility Criteria
Inclusion Criteria
- Smoking adults aged ≥ 18 years intending to quit tobacco use who are prescribed Varenicline (Champix™) by their Physicians and those who are prescribed with Varenicline (Champix™) for the first time.
Exclusion Criteria
- Subjects in whom varenicline (Champix™) may be taken in a manner that is not according to the approved local product document.
- Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception
- Subjects with known hypersensitivity to varenicline.
Data sourced from ClinicalTrials.gov (NCT00794365). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.